...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of hyperthermia: The official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group >CT-guided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma.
【24h】

CT-guided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma.

机译：CT引导的射频消融可延长鼻咽癌肝转移患者的转移生存期。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: The aim of this retrospective study was to evaluate the technical efficacy and survival following CT-guided radiofrequency ablation (RFA) of liver metastases (LM) from nasopharyngeal carcinoma (NPC) and to determine prognostic factors. MATERIALS AND METHODS: Between 2000 and 2008, 376 patients with LM from NPC were identified. Of these 17 patients with 31 LM from NPC underwent CT-guided percutaneous RFA. We assessed the technical effectiveness, complications and prognostic value of LM characteristics including timing (synchronous versus metachronous), number, size, presence of extra hepatic metastases and treatment regimen. Survival rates were calculated using the Kaplan-Meier method. RESULTS: Technical success was achieved in 30/31 metastases (96.7%). The median overall survival was 16.5 months from the time of diagnosis of LM for all the 376 NPC patients with LM, and 48.1 months for the 17 NPC patients with LM who received RFA treatment. Of the 376 patients, 111 had 1-3 LM who did not receive RFA treatment, with a median survival of 25.9 months compared to 48.1 months for the 14 patients with 1-3 LM who received RFA. CONCLUSION: CT-guided RFA of LM from NPC can be performed with a high degree of technical effectiveness and offers the promise of improved survival in selected patients.
机译：目的：这项回顾性研究的目的是评估鼻咽癌（NPC）的肝转移（LM）的CT引导的射频消融（RFA）后的技术疗效和生存率，并确定预后因素。材料与方法：在2000年至2008年之间，共鉴定了376名NPC LM患者。在这17例来自NPC的LM患者中，有31例接受了CT引导的经皮RFA。我们评估了LM特征的技术有效性，并发症和预后价值，包括时机（同步与异时），数量，大小，是否存在肝外转移以及治疗方案。使用Kaplan-Meier方法计算存活率。结果：30/31转移（96.7％）获得了技术成功。所有376例NPC的LM患者自诊断出LM后的中位总生存时间为16.5个月，接受RFA治疗的17例LM的NPC患者的平均生存时间为48.1个月。在376例患者中，有111例1-3 LM未接受RFA治疗，中位生存期为25.9个月，而14例1-3 LM接受RFA治疗的中位生存期为48.1个月。结论：NPC的CT引导的LM的RFA可以高度技术性地执行，并有望改善某些患者的生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号